Sound Income Strategies LLC Buys 2,040 Shares of AbbVie Inc. $ABBV

Sound Income Strategies LLC lifted its position in AbbVie Inc. (NYSE:ABBV) by 2.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 98,943 shares of the company’s stock after acquiring an additional 2,040 shares during the quarter. AbbVie accounts for 0.6% of Sound Income Strategies LLC’s portfolio, making the stock its 17th largest position. Sound Income Strategies LLC’s holdings in AbbVie were worth $26,954,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. GK Wealth Management LLC purchased a new position in AbbVie during the 3rd quarter valued at about $87,000. Balefire LLC lifted its position in shares of AbbVie by 3.1% in the 3rd quarter. Balefire LLC now owns 4,121 shares of the company’s stock worth $1,078,000 after purchasing an additional 124 shares during the period. Riversedge Advisors LLC boosted its stake in shares of AbbVie by 1.8% during the third quarter. Riversedge Advisors LLC now owns 4,748 shares of the company’s stock valued at $1,242,000 after purchasing an additional 82 shares in the last quarter. Wedmont Private Capital increased its holdings in AbbVie by 12.5% during the third quarter. Wedmont Private Capital now owns 49,199 shares of the company’s stock valued at $13,403,000 after buying an additional 5,468 shares during the period. Finally, Intelligence Driven Advisers LLC increased its holdings in AbbVie by 23.2% during the third quarter. Intelligence Driven Advisers LLC now owns 1,477 shares of the company’s stock valued at $386,000 after buying an additional 278 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.06% of the company’s stock.

AbbVie Trading Up 1.4%

Shares of AbbVie stock opened at $276.24 on Friday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $277.60. The firm has a market capitalization of $488.06 billion, a price-to-earnings ratio of 78.03, a PEG ratio of 1.24 and a beta of 0.24. The firm’s 50 day simple moving average is $259.06 and its two-hundred day simple moving average is $236.63.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period last year, the business posted $2.97 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 13.97 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie’s payout ratio is presently 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen AbbVie’s oncology pipeline. The FDA granted two Breakthrough Therapy designations to Temab-A (telisotuzumab adizutecan) for colorectal cancer and non-small cell lung cancer. The designation can accelerate development and regulatory review, although it does not guarantee approval or commercial success. AbbVie’s Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
• Positive Sentiment: Analysts raised their valuation targets. JPMorgan increased its target to $300 and maintained an overweight rating, while Cantor Fitzgerald lifted its target to $290 and Guggenheim reaffirmed a buy rating with a $288 target. These actions suggest analysts see additional upside from AbbVie’s growth products and pipeline. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Positive Sentiment: New products are more than offsetting Humira’s patent-loss decline. Humira revenue fell 35.9% to $756 million, but total quarterly revenue rose 10.2% to $16.99 billion. The performance indicates that immunology, neuroscience and other newer medicines are successfully replacing the former blockbuster. AbbVie Outgrew Humira’s Collapse
• Neutral Sentiment: Valuation and income appeal remain part of the debate. AbbVie’s dividend and defensive characteristics may attract income-focused investors, but the stock’s elevated valuation means continued earnings and pipeline execution are important to justify further gains. Treasury Bills or Dividend Stocks

Analysts Set New Price Targets

Several research analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price target on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday. UBS Group lifted their target price on AbbVie from $260.00 to $275.00 and gave the company a “neutral” rating in a research note on Tuesday. Guggenheim reiterated a “buy” rating and issued a $288.00 target price on shares of AbbVie in a report on Friday. Citigroup increased their price target on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Finally, Scotiabank raised their price target on shares of AbbVie from $280.00 to $320.00 and gave the company an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $277.18.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.